题名：Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
作者：GASTALDELLI A; NAUCK MA; BALENA R;
来源：Metabolism. 2013 Sep;62(9):1330-9. doi: 10.1016/j.metabol.2013.05.001. Epub 2013 [ IF= 0.00 ] ]
摘要：OBJECTIVE: Loss of pancreatic function is pivotal to the deterioration of fasting
and postprandial glycemic control in type 2 diabetes (T2D). We evaluated the
effects of a long-acting, human glucagon-like peptide-1 analog, taspoglutide,
added to metformin, on pancreatic function and peripheral insulin sensitivity.
MATERIALS/METHODS: We studied 80 T2D patients inadequately controlled
[glycosylated hemoglobin (HbA1c), 7.0%-9.5%] receiving stable metformin for
>/=12weeks. They were a subset of participants to a phase 2 trial that received
also a 240-min mixed-meal tolerance test (MTT) at baseline and study end.
Patients received once weekly (QW) sc injection of taspoglutide 5, 10, or 20mg
(n=21, 19, or 19), or placebo (n=21), plus metformin, for 8weeks. We measured
postprandial plasma glucose (PPG) and insulin profiles, insulin secretion rate
(ISR), oral glucose insulin sensitivity (OGIS) index; beta-cell glucose
sensitivity, glucagon/glucose and insulin/glucagon ratios, and insulin
sensitivity-to-insulin resistance (or disposition) index. RESULTS: After 8 weeks
of treatment, taspoglutide 5, 10, and 20mg QW doses vs. placebo improved mean
PPG0-240 min (relative change from baseline: -22.1%, -25.9%, and -22.9% vs.
-8.1%; P<0.005) and mean postprandial ISR0-240 min (+14%, +18%, and +23% vs. +1%;
P<0.005 vs dose). Taspoglutide at 20mg QW dose also resulted in improvements from
baseline in OGIS, beta-cell glucose sensitivity, glucagon/glucose and
insulin/glucagon ratios and the disposition index during the MTT. CONCLUSION:
Taspoglutide QW significantly improved pancreatic function in patients with T2D
treated with metformin.